Study

Anticoagulation

  •   0%
  •  0     0     0

  • What are the two classifications of venous thromboembolism?
    DVT and PE
  • How are argatroban and bivalirudin monitored in HIT?
    aPTT
  • What is the monitoring parameter for a heparin drip?
    anti-Xa or aPTT
  • What is the scoring tool in stroke prevention in afib to assess risk of major bleeding for patients on anticoagulation/
    HAS-BLED
  • What CYP enzyme are apixaban and rivaroxaban metabolized by?
    CYP3A4
  • What are the 3 guidelines used for anticoagulation?
    CHEST, NICE, ASH
  • What criteria screening tool is used for DVT and PE?
    Wells'
  • At what doses of rivaroxaban should a patient be counseled to take with food?
    15 mg or greater
  • What population would a lower starting dose of warfarin be warranted?
    frail, elderly, malnourished, liver/kidney disease, heart failure, or acute illness
  • What is CHADSVASc and the associated scores for each risk factor?
    *see picture*
  • What is the INR goal if the patient has a prosthetic mechanical mitral valve?
    2.5 to 3.5
  • What is Virchow's triad?
    hypercoagulability, stasis, and endothelial injury
  • In VTE treatment, how long must a parenteral agent be on board before transitioning to dabigatran?
    5 days
  • If the patient's INR goal is 2 to 3 and their INR results 3.8 with reported compliance and no change in diet, how would you adjust the dose?
    Withhold no dose to one dose --> Decrease weekly dose by 10% to 15%
  • When is VTE reoccurrence most common?
    First 3 months
  • In patients with cancer with VTE, what is the preferred pharmacological treatment?
    oral Xa inhibitor/DOAC
  • Which DOAC is contraindication if CrCl >95 mL/min?
    edoxaban
  • What are the 4Ts for HIT?
    degree of thrombocytopenia, timing of platelet count, thrombosis of other sequelae, and other causes of thrombocytopenia
  • In stroke prevention in afib, when would warfarin be indicated over a DOAC?
    valvular afib (defined as moderate to severe mitral stenosis or mechanical heart valve)
  • What are the two types of HIT? Which one is clinically important?
    Type I and II; Important: Type II
  • What is the scoring tool for VTE prophylaxis?
    Padua
  • In afib, what are the 3 criteria for dose reduction for apixaban?
    age 80 or greater, weight 60 kg or less, or SCr 1.5 mg/dL or greater
  • What are the two types of pathways in the coagulation cascade?
    intrinsic and extrinsic pathways
  • What agents are non-heparin anticoagulants for HIT?
    argatroban, bivalirudin, fondaparinux, and DOAC (apixaban or rivaroxaban but are off label use), warfarin
  • Which DOAC is recommended if CrCl < 15 mL/min?
    apixaban
  • If the patient's INR goal is 2.5 to 3.5, and INR results less than 2 with reported compliance and no changes in diet, how would you adjust their warfarin?
    Give additional dose and increase weekly dose by 10% to 20%
  • What are the two types of assay utilized in HIT?
    immunoassay and functional assay
  • All DOACs are a substrate of ______
    P-glycoprotein
  • What population would a higher initial dosing of warfarin be warranted?
    young and healthy
  • In HIT, what complex does the antibody recognize?
    complex of PF4 and heparin